Is lurbinectedin approved for breast cancer?
No, lurbinectedin (brand name Zepzelca) is not approved or used as a standard treatment for breast cancer. The FDA approved it in June 2020 specifically for adults with metastatic small cell lung cancer (SCLC) that progressed after platinum-based chemotherapy.[1] Clinical guidelines from NCCN and ESMO list it only for SCLC, not breast cancer subtypes like triple-negative or HER2-positive.[2]
What is lurbinectedin approved for?
Lurbinectedin targets the oncogenic transcription process in tumors, primarily for relapsed SCLC. It's given intravenously every 21 days, often with supportive care for side effects like neutropenia and fatigue. Approval stemmed from the phase 2 ATLANTIS trial showing 35% overall response rate in platinum-sensitive SCLC.[1][3]
Has it been tested in breast cancer trials?
Limited evidence exists from early-phase trials. A phase 1b/2 basket trial (NCT02454972) tested it in advanced solid tumors, including triple-negative breast cancer (TNBC), with some partial responses noted in heavily pretreated patients, but no phase 3 data supports efficacy or approval.[4] Ongoing trials like NCT04702737 explore combinations in gynecologic cancers, not breast. No dedicated breast cancer registration trials are registered on ClinicalTrials.gov as pivotal.
Why not for breast cancer, and what are the alternatives?
Lack of robust phase 3 data in breast cancer limits its use; SCLC's aggressive biology differs from breast cancer's heterogeneity. For metastatic TNBC, standard options include pembrolizumab plus chemo (KEYNOTE-355), sacituzumab govitecan (TRODELVY), or PARP inhibitors for BRCA-mutated cases.[2] Oncologists reserve lurbinectedin for off-label use only in rare, refractory scenarios without strong supporting data.
Who manufactures lurbinectedin and patent status?
Jazz Pharmaceuticals markets Zepzelca after acquiring rights from Pharma Mar. Key U.S. patents expire around 2031-2033, with no generics imminent per DrugPatentWatch.[5] No breast cancer-specific patents apply.
[1] FDA Approval Summary for Zepzelca
[2] NCCN Guidelines for SCLC and Breast Cancer
[3] Trigo et al., Lancet Oncology 2020
[4] ClinicalTrials.gov NCT02454972
[5] DrugPatentWatch: Lurbinectedin Patents